For those looking for a way to invest in early-stage science since the implosion of Woodford Patient Capital Trust, Syncona may offer a tempting alternative.
Its investments focus on areas such as helping the body’s defences to fight cancer. They include gene therapies to combat eye cancer and blindness, and cell therapies to treat diseases of the immune system.
The FTSE 250 company was formed in 2016 through the merger of Battle Against Cancer Investment Trust, a listed vehicle, and Syncona Partners, a life sciences investor set up in 2012.
Last week, Syncona reported results for the three months to December 31 — its net asset value rose by 16 per cent to £1.4 billion, or 199p per share. On Friday, its shares closed at
